Effectiveness of a Hypertension-focused Digital AppLication in a CommunitY Sample: Randomized CONtrolled Trial (“HALCYON”)

Effectiveness of a Hypertension-focused Digital AppLication in a CommunitY Sample: Randomized CONtrolled Trial (“HALCYON”) - HALCYON

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025871

Enrollment

676

Registered

2021-10-05

Start date

2021-10-11

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10-I15

Interventions

Group 1: Intervention group: access to the online program liebria Group 2: Controll group: Treatment-As-Usual

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • at least Stage 1 hypertension (= 135/85 mmHg und < 175/105 mmHg, home-based) • no initial prescription or change of dosage, composition or agent of drug therapy (no new agent) of antihypertensive drug therapy in the past 6 weeks • Sufficient understanding of the German language • Consent to participation

Exclusion criteria

Exclusion criteria: • more than 3 antihypertensive agents (> triple-combination) • secondary hypertension (i.e., thyroid disease, kidney disease) • pregnancy

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure (in mmHg) after 3 months of intervention	—

Secondary

Measure	Time frame
- Responder Rate (calculated based on blood pressure values) - Pulse Pressure (calculated based on blood pressure values) - Quality of life (assessed by WHOQOL-BREF) - Medication adherence (assessed by the Rief Adherence Index, RAI) - Ability to work (assessed by the Work and Social Assessment Scale, WSAS)	—

Countries

Germany

Contacts

Public ContactAnja Specht

GAIA AG

team@liebria-studie.de+49 40 3510520

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026